2. Anti-infection
  3. HIV
  4. 3′-Azido-2′,3′-dideoxyuridine

3′-Azido-2′,3′-dideoxyuridine  (Synonyms: AzdU; AzddU; CS-87)

Cat. No.: HY-106850 Purity: 99.11%
SDS COA Handling Instructions

Molarity Calculator

3′-Azido-2′,3′-dideoxyuridine (AzdU) is a nucleoside analog of Zidovudine (HY-17413). 3′-Azido-2′,3′-dideoxyuridine is a potent inhibitor of human immunodeficiency virus (HIV) replication in human peripheral blood mononuclear cells (PBMC) with limited toxicity for human bone marrow cells (BMC). 3′-Azido-2′,3′-dideoxyuridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

For research use only. We do not sell to patients.

3′-Azido-2′,3′-dideoxyuridine Chemical Structure

3′-Azido-2′,3′-dideoxyuridine Chemical Structure

CAS No. : 84472-85-5

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 94 In-stock
Solution
10 mM * 1 mL in DMSO USD 94 In-stock
Solid
5 mg USD 85 In-stock
10 mg USD 145 In-stock
25 mg USD 300 In-stock
50 mg USD 485 In-stock
100 mg USD 760 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

3′-Azido-2′,3′-dideoxyuridine Related Antibodies

Top Publications Citing Use of Products

View All HIV Isoform Specific Products:

View All Isoforms
HIV HIV-1 HIV-2

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

3′-Azido-2′,3′-dideoxyuridine (AzdU) is a nucleoside analog of Zidovudine (HY-17413). 3′-Azido-2′,3′-dideoxyuridine is a potent inhibitor of human immunodeficiency virus (HIV) replication in human peripheral blood mononuclear cells (PBMC) with limited toxicity for human bone marrow cells (BMC)[1][2][3]. 3′-Azido-2′,3′-dideoxyuridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

IC50 & Target

HIV

 

Cellular Effect
Cell Line Type Value Description References
CCRF-CEM IC50
69.3 μM
Compound: AZU
Cytotoxicity against human CEM cells after 5 days
Cytotoxicity against human CEM cells after 5 days
[PMID: 19948402]
PBMC IC50
> 100 μM
Compound: AZU
Cytotoxicity against human PBMC after 5 days
Cytotoxicity against human PBMC after 5 days
[PMID: 19948402]
Vero IC50
26 μM
Compound: AZU
Cytotoxicity against african green monkey Vero cells after 5 days
Cytotoxicity against african green monkey Vero cells after 5 days
[PMID: 19948402]
In Vitro

3′-Azido-2′,3′-dideoxyuridine inhibits HIV replication in PBMC infected with HIV-1, with a median effective concentration of 0.18-0.46 μM[2].
3′-Azido-2′,3′-dideoxyuridine inhibits HIV-mediated cytopathic effects in the human T-cell lines MT-4 and ATH8, with the median effective of 0.4 µM[3].
3′-Azido-2′,3′-dideoxyuridine is sequentially phosphorylated to its mono-, di-, and triphosphate metabolites by cellular kinases[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

3′-Azido-2′,3′-dideoxyuridine Related Antibodies
In Vivo

3′-Azido-2′,3′-dideoxyuridine (25-100 mg/kg, IV or PO, once) shows good pharmacokinetic profiles[3].
Pharmacokinetic Parameters of 3′-Azido-2′,3′-dideoxyuridine in male Sprague-Dawley rats[3].

IV (25 mg/kg) IV (100 mg/kg) PO (25 mg/kg) PO (100 mg/kg)
Cmax (μg/mL) 9.2±1.9 41±15
Tmax (h) 0.38±0.13 0.63±0.22
AUC (μg/mL∗h) 19±1.2 156±7.0 12±0.54 70±13
CLT (L/h/kg) 1.4±0.2 0.70±0.09
CLR (L/h/kg) 0.90±0.27 0.43±0.12
t1/2 (h) 0.5±0.0 0.68±0.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Adult male Sprague-Dawley rats (300-400 g)[3]
Dosage: 25, 100 mg/kg
Administration: Intravenous bolus injection or oral gavage (Pharmacokinetic Analysis)
Result: The oral bioavailability estimates of 3′-Azido-2′,3′-dideoxyuridine at doses of 25 and 100 mg/kg averaged 53%.
Molecular Weight

253.21

Formula

C9H11N5O4
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

OC[C@H]([C@@H](N=[N+]=[N-])C1)O[C@H]1N(C=C2)C(NC2=O)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 250 mg/mL (987.32 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.9493 mL 19.7465 mL 39.4929 mL
5 mM 0.7899 mL 3.9493 mL 7.8986 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.08 mg/mL (8.21 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.08 mg/mL (8.21 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 3.9493 mL 19.7465 mL 39.4929 mL 98.7323 mL
5 mM 0.7899 mL 3.9493 mL 7.8986 mL 19.7465 mL
10 mM 0.3949 mL 1.9746 mL 3.9493 mL 9.8732 mL
15 mM 0.2633 mL 1.3164 mL 2.6329 mL 6.5822 mL
20 mM 0.1975 mL 0.9873 mL 1.9746 mL 4.9366 mL
25 mM 0.1580 mL 0.7899 mL 1.5797 mL 3.9493 mL
30 mM 0.1316 mL 0.6582 mL 1.3164 mL 3.2911 mL
40 mM 0.0987 mL 0.4937 mL 0.9873 mL 2.4683 mL
50 mM 0.0790 mL 0.3949 mL 0.7899 mL 1.9746 mL
60 mM 0.0658 mL 0.3291 mL 0.6582 mL 1.6455 mL
80 mM 0.0494 mL 0.2468 mL 0.4937 mL 1.2342 mL
100 mM 0.0395 mL 0.1975 mL 0.3949 mL 0.9873 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

3′-Azido-2′,3′-dideoxyuridine Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

3′-Azido-2′,3′-dideoxyuridine84472-85-5AzdU AzddU CS-87CS87CS 87CS-87HIVHuman immunodeficiency virusPBMCHIV-1T-cell linesMT-4ATH8Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
3′-Azido-2′,3′-dideoxyuridine
Cat. No.:
HY-106850
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.